Tourette’s Study for Adults

$50 per completed visit

Study Specific Details:

  • Ecopipam vs. Placebo.  This is a double-blind, placebo-controlled study to evaluate the safety and efficacy of Ecopipam in children, teens and adults.
  • Psychological therapies or deep brain stimulation are okay as long as they have been stable for 10 weeks or longer prior to baseline. 
  • Fasting at screening is optional.
  • 24-week treatment period. 
  • Inclusion
  • Exclusion
  • Must be 18 years or older to participate.
  • Tourette's Disorder must be primary. 
  • Must exhibit both motor and vocal tics that cause impairment with normal routines.
  • Medication for the treatment of motor or vocal tics will have a 14-day washout period prior to baseline.
  • Current PHQ-9 score of 10 or higher. 
  • Must not have had an onset of a major depressive episode in the past 6 months. 
  • Lifetime history of dementia, bipolar disorder, schizophrenia, or any psychotic disorder.
  • Previous treatment of Ecopipam or oral antipsychotics within 4 weeks of screening, depot antipsychotics within 3 months of screening. 
  • Antidepressants, antipsychotics and anti-ADHD medications. 
  • Medications that may have unfavorable interactions with study medication: P-gp, CYP2D6 inhibitors to include fluoxetine or APTP1B1 substrates w/ narrow therapeutic window, dopamine antagonists or agonists, MAOI's and St. John's Wart. 
  • Subject with any unstable mood disorder. 
  • Current or recent within the past 3 months of substance use disorder (except for nicotine). 
  • Siblings or family members of any current subject participating in the study.  
  • History of seizures (excluding febrile seizures that occurred >2 years prior to screening).
  • History of a suicide attempt.
  • Huntington's disease, Parkinson's disease, Wilson's disease, stroke and Restless legs Syndrome.  
Questions? Give Us A Call!

Contact Us

Want to learn more about Harmonex Neuroscience Research?